ArticleJournal of neuromuscular diseases2026
Longitudinal treatment patterns in myasthenia gravis: An analysis from the prospective Dutch-Belgian patient registry.
Article in Journal of neuromuscular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS.Journal of neuromuscular diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding treatment patterns in myasthenia gravis (MG) is crucial for clinical practice. However, longitudinal data are limited.
objectiveThis study aimed to provide an overview of treatment patterns in different subgroups throughout the disease course.
methodsAll adult patients with acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or seronegative MG enrolled in the Dutch-Belgian myasthenia registry were included. AChR-MG patients were classified into early-onset (EOMG) (≤50 years) and late-onset (LOMG) (>50 years) MG. Mixed-effects regression was used to compare differences between the different subgroups.
resultsA total of 506 patients were included (147 AChR EOMG, 265 AChR LOMG, 26 MuSK, and 94 seronegative MG patients). Data were available within a year of diagnosis for 84 patients. Most patients initially started treatment with pyridostigmine (93%; 78/84), followed by corticosteroids (52%; 44/84) and azathioprine or mycophenolate mofetil (30%; 25/84). After ten years, the use of pyridostigmine (65%; 54/83) and corticosteroid use (36%; 30/83) declined, whereas the use of azathioprine and mycophenolate mofetil increased (55%; 46/83). Seronegative patients received fewer treatments than AChR MG patients, independent of functional status and disease duration (OR 0.38, 95% CI 0.17-0.84, p = 0.018), and were less likely to use corticosteroids (OR 0.15, 95% CI [0.05-0.41], p < 0.001). Patients with LOMG reported more frequently immunosuppressive use compared to patients with EOMG (OR 4.69, 95% CI 1.16-19.02, p = 0.031).
conclusionsThis analysis offers valuable insights into treatment patterns in different subgroups of patients with MG. A substantial proportion of patients continues to rely on corticosteroids, suggesting an ongoing need for alternative treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.